No Data
No Data
Hong Kong stock abnormal | CRO concept stocks rebounded in the morning, overseas investment and financing gradually recovered. The pharmaceutical subdivision field and emerging businesses are expected to develop rapidly.
Concept stocks of CRO rebounded in early trading. As of the time of writing, Genscript Bio (01548) rose by 4.39% to HK$10.94; Tigermed (03347) rose by 4.47% to HK$33.85; Frontage (01521) rose by 2.75% to HK$1.12; Joinn Laboratories (06127) rose by 2.49% to HK$9.47; Wuxi Bio (02269) rose by 1.68% to HK$14.54.
Contract research organizations concept rises, Joinn Laboratories (06127) rises by 5.11%, institutions say CXO sector is expected to benefit from the recovery of overseas research and development demand.
Jinwu Financial News | The concept of contract research organizations has risen across the board, with joinn laboratories (06127) up 5.11%, tigermed (03347) up 4.33%, frontage (01521) up 2%, pharmaron (03759) up 1.84%, and wuxi bio (02269) up 0.79%. Zhongtai reported that the bank believes that as the medical insurance fund prepayment system continues to deepen and improve, and the supporting DRG/DIP system is continuously implemented in various provinces and cities, the long-term "triangle debt" relationship among hospitals, pharmaceutical companies, and medical insurance persists, and the "zero markup policy on pharmaceuticals" compresses hospital profitability.
Trending Industry Today: WUXI APPTEC Leads Losses In CRO Stocks
Frontage Holdings Corporation's (HKG:1521) P/E Is Still On The Mark Following 35% Share Price Bounce
We Think Frontage Holdings (HKG:1521) Is Taking Some Risk With Its Debt
Frontage (01521) granted 33.15 million share options.
Frontage (01521) announced in a statement that on October 30, 2024 (after the trading session), according to the public...
No Data
No Data